LSB (LakeShore Biopharma Co) EV-to-EBIT : -2.95 (As of May. 13, 2025)

LakeShore Biopharma Co EV-to-EBIT Chart

LakeShore Biopharma Co Quarterly Data
	Mar21	Mar22	Jun22	Sep22	Mar23	Jun23	Sep23	Mar24	Sep24
EV-to-EBIT	Get a 7-Day Free Trial				-10.17	-29.70	-5.12	-2.83	-

Competitive Comparison of LakeShore Biopharma Co's EV-to-EBIT

For the Biotechnology subindustry, LakeShore Biopharma Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's EV-to-EBIT falls into.

LakeShore Biopharma Co EV-to-EBIT Calculation

LakeShore Biopharma Co's EV-to-EBIT for today is calculated as:

LakeShore Biopharma Co's current Enterprise Value is $66.22 Mil.
LakeShore Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co  (NAS:LSB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

LakeShore Biopharma Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

LakeShore Biopharma Co's Enterprise Value for the quarter that ended in Sep. 2024 was $175.23 Mil.
LakeShore Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co Business Description